Sen-Jam Pharmaceutical has enrolled patients in a Phase 2 Clinical Trial for a covid oral therapeutic in collaboration with Duke University. They are also preparing for a Phase 2 clinical trial for the prevention of alcohol’s toxic effects.
Organizations Involved
Duke University
Founders
James Iversen, Jacqueline M. Iversen, Neal Zahn
Company Description
Sen-Jam Pharmaceutical is developing a line of anti-inflammatory drugs designed to provide a much-needed update to a multi-billion dollar market that has seen little innovation in the past 30 years. They are focusing on harnessing the body’s immune system at the beginning of the inflammatory cascade to prevent acute inflammation, slow the progression of chronic illnesses, and improve health span.